Valneva Stock (VALN) Soars Over 20% On Lyme Disease Vaccine Hopes
TipRanks (Fri, 14-Aug 9:47 AM ET)
Valneva Stock (VLN) Soars Over 20% On Lyme Disease Vaccine Hopes
TipRanks (Fri, 14-Aug 9:47 AM ET)
Guggenheim Reaffirms Their Buy Rating on Valneva (VALN)
TipRanks (Fri, 14-Aug 8:18 AM ET)
Market Chameleon (Fri, 14-Aug 3:05 AM ET)
Valneva jumps as Lyme disease vaccine developed with Pfizer undergoes EU review
Seeking Alpha News (Fri, 14-Aug 6:46 AM ET)
TipRanks (Fri, 14-Aug 6:30 AM ET)
Business Wire (Fri, 14-Aug 1:00 AM ET)
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
Globe Newswire (Thu, 13-Aug 1:00 AM ET)
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
Globe Newswire (Wed, 22-Jul 11:45 AM ET)
Valneva Announces Successful Outcome of its Annual General Meeting
Globe Newswire (Thu, 25-Jun 11:45 AM ET)
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Valneva Se - American Depositary Shares trades on the NASDAQ stock market under the symbol VALN.
As of August 19, 2026, VALN stock price climbed to $6.90 with 30,780 million shares trading.
VALN has a beta of 2.44, meaning it tends to be more sensitive to market movements. VALN has a correlation of 0.13 to the broad based SPY ETF.
VALN has a market cap of $654.28 million. This is considered a Small Cap stock.
Last quarter Valneva Se - American Depositary Shares reported $41 million in Revenue and -$.40 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.12.
In the last 3 years, VALN traded as high as $14.94 and as low as $3.62.
VALN has underperformed the market in the last year with a return of -43.2%, while SPY returned +21.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in VALN shares. However, VALN has outperformed the market in the last 3 month and 2 week periods, returning +20.8% and +34.2%, while SPY returned +4.7% and 0.0%, respectively. This indicates VALN has been having a stronger performance recently.
VALN support price is $6.62 and resistance is $7.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VALN shares will trade within this expected range on the day.